Disease relevance of RNF125

• Multivariable analyses showed that only the bone resorption markers TRACP 5b, CTX and ICTP, and the marker of angiogenesis VEGF were independently associated with BM [1].
• The combination of TRACP with ICTP did not significantly improve the detection of bone metastases over tALP [2].
• It should have applications in evaluating patients with bone disease and will improve our understanding of the biological significance of TRACP 5b expression in health and disease [3].
• Mean serum TRACP 5b was significantly increased in ESRD with both immunoassays [3].

High impact information on RNF125

• Osteoclasts were stained for TRACP, and the dentine slices were examined for evidence of resorption [4].
• Tissue mast cells displayed strong TRACP staining [5].
• Our goal was to determine if serum TRACP-5a could originate from inflammatory macrophages (MPhi) [5].
• Marginal zone lymphocytes and sebaceous glands of skin were weakly positive for TRACP [5].
• Noninflammatory MPhi in lymph node sinuses or germinal centers and red pulp MPhi of spleen were weak or negative for TRACP [5].

Biological context of RNF125

• The utility, prognostic implications and limitations of classical and novel markers of bone remodeling (e.g. ICTP, NTx, TRACP-5b, osteoprotegerin, sRANKL) will be discussed in this overview [6].
• With the combination of TRACP 5b and ICTP, the AUC increased to 0.881 [2].
• SEARCH STRATEGY: We searched MEDLINE, EMBASE, CENTRAL, Current Awareness in Clinical Toxicology, Info Trac, http://www.google.com.au, and Science Citation Index of studies identified by the previous searches [7].

Associations of RNF125 with chemical compounds

• Pit formation, TRACP staining, RANKL dose response, osteoclast markers, acid secretion, F-actin ring, and integrin alpha(v)beta3 expression and co-localization were studied [8].
• Bortezomib administration significantly reduced serum DKK-1, sRANKL, CTX, and TRACP-5b after four cycles, and dramatically increased bone-alkaline phosphatase and osteocalcin, irrespective of treatment response [9].
• OBJECTIVE: Our purpose was to develop a specific immunoassay for tartrate-resistant acid phosphatase (TRACP) 5b using naphthol ASBI phosphate (N-ASBI-P) as a selective substrate for isoform 5b and heparin as a selective inhibitor of isoform 5a [3].
• METHODS: Therefore, we switched the dialysate calcium concentration from 1.5 - 1.25 mmol/l and observed the effects on serum calcium (S-Ca), phosphorus (S-P), 1-84 parathyroid hormone (whole PTH, w-PTH), bone-specific alkaline phosphatase (BAP), and tartrate-resistant acid phosphatase isoform 5b (TRACP-5b) for 6 months in 58 hemodialysis patients [10].

Analytical, diagnostic and therapeutic context of RNF125

• CONCLUSION: This alternative immunoassay for TRACP 5b activity is highly specific [3].
• BACKGROUND: The purpose of this cross-sectional study was to evaluate the value of serum tartrate-resistant acid phosphatase 5b (TRACP 5b) and carboxyterminal telopeptide of type I collagen (ICTP) separately and in combination as markers of bone metastases compared to total alkaline phosphatase (tALP) in breast cancer [2].
• Serum TRACP 5b levels correlated significantly with NTX and bone ALP in the disease groups, but not always in the control group [3].

References